695 related articles for article (PubMed ID: 10650787)
1. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
2. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
[TBL] [Abstract][Full Text] [Related]
3. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).
Kahán Z; Spanik S; Wagnerova M; Skacel T; Planko B; Fitzthum E; Lindner E; Soldatenkova V; Zielinski CC; Brodowicz T
Breast Cancer Res Treat; 2008 Dec; 112(3):557-63. PubMed ID: 18189160
[TBL] [Abstract][Full Text] [Related]
7. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
8. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
[TBL] [Abstract][Full Text] [Related]
10. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
11. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.
Erselcan T; Kairemo KJ; Wiklund TA; Hernberg M; Blomqvist CP; Tenhunen M; Bergh J; Joensuu H
Br J Cancer; 2000 Feb; 82(4):777-81. PubMed ID: 10732745
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer.
Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R
Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Hui R; Zhang M; Hao XM; Zhang J
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):871-4. PubMed ID: 18396651
[TBL] [Abstract][Full Text] [Related]
14. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
15. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients.
Filip S; Vanásek J; Bláha M; Mericka P; Vávrová J; Podzimek K
Neoplasma; 1999; 46(3):166-72. PubMed ID: 10613592
[TBL] [Abstract][Full Text] [Related]
16. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
Cottu PH; Extra JM; Espie M; Marolleau JP; de Roquancourt A; Makke J; Miclea JM; Laurence V; Mayeur D; Lerebours F; Cuvier C; Marty M
Br J Cancer; 2001 Nov; 85(9):1240-6. PubMed ID: 11720455
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
[TBL] [Abstract][Full Text] [Related]
18. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
[TBL] [Abstract][Full Text] [Related]
19. [The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer].
Honda S; Toi M; Shimizu S; Hayashi K; Tominaga T
Gan To Kagaku Ryoho; 1997 Apr; 24(6):679-83. PubMed ID: 9126304
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.
Sessa C; Pagani O; Parma G; Goldhirsch A; Cavalli F
Semin Oncol; 1995 Jun; 22(3 Suppl 6):112-7. PubMed ID: 7541152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]